Legendary Creatures has teamed up with Noile-Immun

, legendary biotech, a cell therapy research and development company, announced a partnership agreement with Noile-Immune Biotech ("Noile-Immune"), an innovative cancer immunotherapy biotech. Legendary Creatures and Noile-Immune will work together on two specific cancer targets, and Legendary Creatures will have the right to apply Noile-Immune's core PRIME (Proliferation inducing and migration induction, proliferation induction and enhanced migration) technology to its cell development pipelines to develop secretive IL-7 and CC L19's CAR-T and/or TCR-T cell therapy, while Legendary Bio will pay About $70 million to Noile-Immune for partial development, regulatory and commercial milestones, and Noile-Immune will be entitled to royalties for the commercial sale of its products.Founded in April 2015 in Tokyo, Japan, Noile-Immune is a clinical-stage biotechnology company focused on the development and commercialization of solid tumor CAR-T therapies, and its PRIME technology promotes the amplification, accumulation and induction of CAR-T and/or TCR-T cells and the patient's own T-cells in solid tumors.Prime technology works by genetically engineering T cells to express cytokines and coercion factors such as IL-7 and CCL19. IL-7 promotes T-cell proliferation while maintaining T-cell stability, while CCL19 can collect exocyte T-cells and dedes into lymphatic tissue.Previous studies have shown that the new generation of CAR-T, which expresses IL-7 and CCL19, has twice the proliferative capacity of ordinary CAR-T cells and can induce a large number of the body's own T-cells and dendrites to effectively immerse in the internal tissues of solid tumors, killing tumor cells.At present, legendary organisms in the field of cell therapy has laid out a number of pipelines, its clinical trials in China and the United States have also entered the clinical II, III stage, the fastest progress of the BCMA CAR-T therapy LCAR-B38M / JNJ-452 has been awarded by the FDA orphan drug qualification, breakthrough therapy qualification and the European Medicines Agency PRIME qualification. The partnership with Noile-Immune will further promote the development of its cellular drugs.In March, Legendary Bio's parent company, Kingsley Biotech (01548-HK), announced that it had submitted to the Stock Exchange of Hong Kong Limited, in accordance with the 15th Application Guidelines, a proposal for a spin-off ("recommended spin-off") of its cell therapy business through a registered public offering on an accredited stock exchange in the United States.The announcement also revealed that the Stock Exchange had agreed to a proposed spin-off of Kingsley and that Legendary had confidentially filed a draft registration statement with the Securities and Exchange Commission on March 9, 2020 (New York time) relating to the proposed initial public offering of American Depositary Shares representing its common stock. In the future, Legendary Creatures may be split from Kingsley and listed independently in the United States. (
Medical
)